Abstract:Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient's T-cells to express membrane spanning fusion receptors with defined specificities for tumor-associated antigens. These CARs are capable of eliciting robust T-cell activation to initiate killing of the target tumor cells. This therapeutic approach has produced unprecedented clinical outcomes in the treatment of "liquid" hematologic cancers, but to date has not produced comparable responses in targeting solid malignancies. Advances in our understanding of the immunobiology of solid tumors have highlighted several hurdles which currently hinder the efficacy of this therapy. These barriers include the insufficient accumulation of CAR T-cells in the tumor due to poor trafficking or physical exclusion and the exposure of infiltrating CAR T-cells to a panoply of immune suppressive checkpoint molecules, cytokines, and metabolic stresses that are not conducive to efficient immune reactions and can thereby render these cells anergic, exhausted, or apoptotic. This mini-review summarizes these hurdles and describes some recent approaches and innovations to genetically re-engineer CAR T-cells to counter inhibitory influences found in the tumor microenvironment. Novel immunotherapy drug combinations to potentiate the activity of CAR T-cells are also discussed. As our understanding of the immune landscape of tumors improves and our repertoire of immunotherapeutic drugs expands, it is envisaged that the efficacy of CAR T-cells against solid tumors might be potentiated using combination therapies, which it is hoped may lead to meaningful improvements in clinical outcome for patients with refractory solid malignancies.

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

CAR Cells beyond Classical CAR T Cells: Functional Properties and Prospects of Application

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

CAR T cells: Building on the CD19 paradigm

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Driving CAR T-cells forward

CAR T-Cell Therapy: The Next Frontier for Cancer Immunotherapy

Immunogenicity of CAR T cells in cancer therapy

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review